This morning, Johnson & Johnson shared its second-quarter performance.
Since its founding in 1886, the company has grown to become the world’s largest, most diversified healthcare products company, with more than 150,000 employees across the globe working every day to help change the trajectory of health for humanity.
“Johnson & Johnson delivered strong second quarter results. We executed against our long-term business strategy by attaining key clinical and regulatory milestones in our Pharmaceutical and MedTech businesses and made considerable progress toward the separation of Kenvue,” says Joe Wolk, Executive Vice President and Chief Financial Officer, Johnson & Johnson. “These advancements provide a strong foundation for the long-term growth of the company and are reflective of the dedication of our colleagues around the world. We will continue to invest in innovation that brings transformational treatments to patients and delivers long-term value to shareholders.”
For more details about the company’s 2023 second-quarter results, and to read a message from Chairman of the Board and Chief Executive Officer Joaquin Duato, here’s an infographic that highlights key stats.
Johnson & Johnson’s 2023 2nd-Quarter Earnings
You are now leaving jnj.com
The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Want to see more company earnings information? Find Johnson & Johnson’s past quarterly and full-year results here.
